Table 1 illustrates that the most significant obstacles to progress across these systems have not been a lack of physiological relevance, but unresolved pharmacologic, technological, or conceptual challenges
Lowering prices might encourage more people who might benefit from these medications to start using them. Recently, the IIFH brought together leading scientists, industry innovators and health care experts to examine how GLP-1-based therapies are transforming obesity and diabetes care
Its going to get complicated quickly. AARP will help provide information about the program and follow its rollout for potential problems that Medicare enrollees may encounter in trying to access the benefit, Purvis says
From payer friction to behavioral drop-off, GLP-1s are challenging pharma to rethink how success is measured in the obesity and diabetes markets
The development of novel drug delivery systems or formulations is also essential to improve patient compliance and reduce gastrointestinal adverse effects
Costs $15 to $25 for 30ml which reconstitutes dozens of vials
